|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/19/16 AbbVie Inc. 10-K 12/31/15 97:20M Toppan Merrill-FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.54M
2: EX-10.4 Material Contract HTML 124K
3: EX-10.5 Material Contract HTML 123K
4: EX-10.6 Material Contract HTML 92K
5: EX-10.8 Material Contract HTML 134K
7: EX-21 Subsidiaries List HTML 128K
8: EX-23 Consent of Experts or Counsel HTML 29K
6: EX-12 Statement re: Computation of Ratios HTML 35K
9: EX-31.1 Certification -- §302 - SOA'02 HTML 31K
10: EX-31.2 Certification -- §302 - SOA'02 HTML 31K
11: EX-32.1 Certification -- §906 - SOA'02 HTML 28K
12: EX-32.2 Certification -- §906 - SOA'02 HTML 28K
19: R1 Document and Entity Information HTML 53K
20: R2 Consolidated Statements of Earnings HTML 80K
21: R3 Consolidated Statements of Earnings HTML 31K
(Parenthetical)
22: R4 Consolidated Statements of Comprehensive Income HTML 48K
23: R5 Consolidated Statements of Comprehensive Income HTML 39K
(Parenthetical)
24: R6 Consolidated Balance Sheets HTML 103K
25: R7 Consolidated Balance Sheets (Parenthetical) HTML 35K
26: R8 Consolidated Statements of Equity HTML 87K
27: R9 Consolidated Statements of Cash Flows HTML 129K
28: R10 Background and Basis of Presentation HTML 38K
29: R11 Summary of Significant Accounting Policies HTML 125K
30: R12 Supplemental Financial Information HTML 110K
31: R13 Earnings Per Share HTML 34K
32: R14 Licensing, Acquisitions and Other Arrangements HTML 114K
33: R15 Collaboration with Janssen Biotech, Inc. HTML 33K
34: R16 Goodwill and Intangible Assets HTML 134K
35: R17 Restructuring Plans HTML 59K
36: R18 Debt, Credit Facilities, and Commitments and HTML 192K
Contingencies
37: R19 Financial Instruments and Fair Value Measures HTML 495K
38: R20 Post-Employment Benefits HTML 597K
39: R21 Equity HTML 332K
40: R22 Income Taxes HTML 276K
41: R23 Legal Proceedings and Contingencies HTML 44K
42: R24 Segment and Geographic Area Information HTML 145K
43: R25 Quarterly Financial Data (Unaudited) HTML 105K
44: R26 Summary of Significant Accounting Policies HTML 198K
(Policies)
45: R27 Summary of Significant Accounting Policies HTML 88K
(Tables)
46: R28 Supplemental Financial Information (Tables) HTML 116K
47: R29 Licensing, Acquisitions and other Arrangements HTML 100K
(Tables)
48: R30 Goodwill and Intangible Assets (Tables) HTML 130K
49: R31 Restructuring Plans (Tables) HTML 56K
50: R32 Debt, Credit Facilities, and Commitments and HTML 190K
Contingencies (Tables)
51: R33 Financial Instruments and Fair Value Measures HTML 489K
(Tables)
52: R34 Post-Employment Benefits (Tables) HTML 615K
53: R35 Equity (Tables) HTML 324K
54: R36 Income Taxes (Tables) HTML 279K
55: R37 Segment and Geographic Area Information (Tables) HTML 143K
56: R38 Quarterly Financial Data (Unaudited) (Tables) HTML 103K
57: R39 Background and Basis of Presentation (Details) HTML 55K
58: R40 Summary of Significant Accounting Policies HTML 32K
(Details)
59: R41 Summary of Significant Accounting Policies HTML 46K
(Details 2)
60: R42 Summary of Significant Accounting Policies HTML 75K
(Details 3)
61: R43 Supplemental Financial Information (Details) HTML 78K
62: R44 Earnings Per Share (Details) HTML 54K
63: R45 Licensing, Acquisitions and Other Arrangements HTML 109K
(Details)
64: R46 Licensing, Acquisitions and Other Arrangements HTML 107K
(Details 2)
65: R47 Licensing, Acquisitions and Other Arrangements HTML 113K
(Details 3)
66: R48 Collaboration with Janssen Biotech, Inc. (Details) HTML 54K
67: R49 Goodwill and Intangible Assets (Details) HTML 91K
68: R50 Goodwill and Intangible Assets (Details 2) HTML 33K
69: R51 Restructuring Plans (Details) HTML 29K
70: R52 Restructuring Plans (Details 2) HTML 40K
71: R53 Debt, Credit Facilities, and Commitments and HTML 135K
Contingencies (Details)
72: R54 Debt, Credit Facilities, and Commitments and HTML 80K
Contingencies (Details 2)
73: R55 Financial Instruments and Fair Value Measures HTML 69K
(Details)
74: R56 Financial Instruments and Fair Value Measures HTML 47K
(Details 2)
75: R57 Financial Instruments and Fair Value Measures HTML 79K
(Details 3)
76: R58 Financial Instruments and Fair Value Measures HTML 34K
(Details 4)
77: R59 Financial Instruments and Fair Value Measures HTML 44K
(Details 5)
78: R60 Financial Instruments and Fair Value Measures HTML 52K
(Details 6)
79: R61 Financial Instruments and Fair Value Measures HTML 69K
(Details 7)
80: R62 Post-Employment Benefits (Details) HTML 212K
81: R63 Post-Employment Benefits (Details 2) HTML 141K
82: R64 Post-Employment Benefits (Details 3) HTML 30K
83: R65 Equity (Details) HTML 164K
84: R66 Equity (Details 2) HTML 82K
85: R67 Equity (Details 3) HTML 99K
86: R68 Equity (Details 4) HTML 62K
87: R69 Income Taxes (Details) HTML 126K
88: R70 Income Taxes (Details 2) HTML 34K
89: R71 Income Taxes (Details 3) HTML 39K
90: R72 Income Taxes (Details 4) HTML 58K
91: R73 Legal Proceedings and Contingencies (Details) HTML 55K
92: R74 Segment and Geographic Area Information (Details) HTML 85K
93: R75 Segment and Geographic Area Information (Details HTML 73K
2)
94: R76 Quarterly Financial Data (Unaudited) (Details) HTML 106K
96: XML IDEA XML File -- Filing Summary XML 169K
95: EXCEL IDEA Workbook of Financial Reports XLSX 129K
13: EX-101.INS XBRL Instance -- abbv-20151231 XML 6.85M
15: EX-101.CAL XBRL Calculations -- abbv-20151231_cal XML 289K
16: EX-101.DEF XBRL Definitions -- abbv-20151231_def XML 1.10M
17: EX-101.LAB XBRL Labels -- abbv-20151231_lab XML 2.45M
18: EX-101.PRE XBRL Presentations -- abbv-20151231_pre XML 1.64M
14: EX-101.SCH XBRL Schema -- abbv-20151231 XSD 263K
97: ZIP XBRL Zipped Folder -- 0001047469-16-010239-xbrl Zip 342K
Exhibit 21
SUBSIDIARIES OF ABBVIE INC.
The following is a list of subsidiaries of AbbVie Inc. AbbVie Inc. is not a subsidiary of any other corporation. Where ownership of a subsidiary is less than 100% by AbbVie Inc. or an AbbVie Inc. subsidiary, such has been noted by designating the percentage of ownership.
|
Domestic Subsidiaries |
|
Incorporation |
|
|
|
|
|
AbbVie Biopharmaceuticals LLC |
|
Delaware |
|
|
|
|
|
AbbVie Bioresearch Center Inc. |
|
Delaware |
|
|
|
|
|
AbbVie Biotech Ventures Inc. |
|
Delaware |
|
|
|
|
|
AbbVie Biotherapeutics Inc. |
|
Delaware |
|
|
|
|
|
AbbVie Endocrine Inc. |
|
Delaware |
|
|
|
|
|
AbbVie Endocrinology Inc. |
|
Delaware |
|
|
|
|
|
AbbVie Holdings Inc. |
|
Delaware |
|
|
|
|
|
AbbVie Products LLC |
|
Georgia |
|
|
|
|
|
AbbVie Purchasing LLC |
|
Delaware |
|
|
|
|
|
AbbVie Resources Inc. |
|
Delaware |
|
|
|
|
|
AbbVie Resources International Inc. |
|
Delaware |
|
|
|
|
|
AbbVie Respiratory LLC |
|
Delaware |
|
|
|
|
|
AbbVie US Holdings LLC |
|
Delaware |
|
|
|
|
|
AbbVie US LLC |
|
Delaware |
|
|
|
|
|
AbbVie Ventures LLC |
|
Delaware |
|
|
|
|
|
Aeropharm Technology, LLC |
|
Delaware |
|
|
|
|
|
BioDisplay Technologies, Inc. |
|
Illinois |
|
|
|
|
|
Fremont Holding L.L.C. |
|
Delaware |
|
|
|
|
|
IEP Pharmaceutical Devices, LLC |
|
Delaware |
|
|
|
|
|
Knoll Pharmaceutical Company |
|
New Jersey |
|
|
|
|
|
KOS Pharmaceuticals, Inc. |
|
Delaware |
|
|
|
|
|
Life Properties Inc. |
|
Delaware |
|
|
|
|
|
Organics L.L.C. |
|
Delaware |
|
Pharmacyclics LLC |
|
Delaware |
|
|
|
|
|
Rowell Laboratories, Inc. |
|
Minnesota |
|
|
|
|
|
Sapphire Merger Sub, Inc. |
|
Delaware |
|
|
|
|
|
Unimed Pharmaceuticals, LLC |
|
Delaware |
|
|
|
|
|
Vernal Holdings Inc. |
|
Delaware |
|
Foreign Subsidiaries |
|
Incorporation |
|
|
|
|
|
AbbVie S.A. |
|
Argentina |
|
|
|
|
|
AbbVie Pty Ltd |
|
Australia |
|
|
|
|
|
AbbVie GmbH |
|
Austria |
|
|
|
|
|
AbbVie Bahamas Ltd. |
|
Bahamas |
|
|
|
|
|
AbbVie SA |
|
Belgium |
|
|
|
|
|
AbbVie Ltd |
|
Bermuda |
|
|
|
|
|
AbbVie Biotechnology Ltd |
|
Bermuda |
|
|
|
|
|
AbbVie Holdings Unlimited |
|
Bermuda |
|
|
|
|
|
AbbVie d.o.o. |
|
Bosnia |
|
|
|
|
|
AbbVie Farmacêutica Ltda. |
|
Brazil |
|
|
|
|
|
AbbVie Participações Ltda. |
|
Brazil |
|
|
|
|
|
AbbVie EOOD |
|
Bulgaria |
|
|
|
|
|
AbbVie Corporation |
|
Canada |
|
|
|
|
|
AbbVie Holdings Corporation |
|
Canada |
|
|
|
|
|
Pharmacyclics Cayman Ltd. |
|
Cayman Islands |
|
|
|
|
|
AbbVie Productos Farmacéuticos Limitada |
|
Chile |
|
|
|
|
|
AbbVie Pharmaceutical Trading (Shanghai) Co., Ltd. |
|
China |
|
Pharmacyclics (Shanghai) Management Consulting Services Limited |
|
China |
|
|
|
|
|
AbbVie S.A.S. |
|
Colombia |
|
|
|
|
|
AbbVie d.o.o. |
|
Croatia |
|
|
|
|
|
AbbVie Limited |
|
Cyprus |
|
|
|
|
|
AbbVie s.r.o. |
|
Czech Republic |
|
|
|
|
|
AbbVie A/S |
|
Denmark |
|
|
|
|
|
AbbVie, S.R.L. |
|
Dominican Republic |
|
|
|
|
|
AbbVie Ltd. |
|
Egypt |
|
|
|
|
|
AbbVie Oy |
|
Finland |
|
|
|
|
|
AbbVie SAS |
|
France |
|
|
|
|
|
AbbVie Holdings SAS |
|
France |
|
|
|
|
|
Abbott Products GmbH |
|
Germany |
|
|
|
|
|
AbbVie Biotechnology GmbH |
|
Germany |
|
|
|
|
|
AbbVie Deutschland GmbH & Co. KG |
|
Germany |
|
|
|
|
|
AbbVie Komplementär GmbH |
|
Germany |
|
|
|
|
|
AbbVie Real Estate Management GmbH |
|
Germany |
|
|
|
|
|
AbbVie (Gibraltar) Holdings Limited |
|
Gibraltar |
|
|
|
|
|
AbbVie (Gibraltar) Limited |
|
Gibraltar |
|
|
|
|
|
AbbVie Pharmaceuticals Societe Anonyme |
|
Greece |
|
|
|
|
|
AbbVie, S.A. |
|
Guatemala |
|
|
|
|
|
AbbVie Limited |
|
Hong Kong |
|
|
|
|
|
AbbVie Kft. |
|
Hungary |
|
|
|
|
|
AbbVie Ireland Holdings Limited |
|
Ireland |
|
AbbVie Ireland Unlimited Company |
|
Ireland |
|
|
|
|
|
AbbVie Limited |
|
Ireland |
|
|
|
|
|
AbbVie Manufacturing Management Limited |
|
Ireland |
|
|
|
|
|
Fournier Laboratories Ireland Ltd. |
|
Ireland |
|
|
|
|
|
Pharmacyclics (Europe) Limited |
|
Ireland |
|
|
|
|
|
AbbVie Biopharmaceuticals Ltd. |
|
Israel |
|
|
|
|
|
AbbVie S.r.l. |
|
Italy |
|
|
|
|
|
AbbVie GK |
|
Japan |
|
|
|
|
|
AbbVie Holdings KK |
|
Japan |
|
|
|
|
|
AbbVie Ltd |
|
Jersey |
|
|
|
|
|
AbbVie UK Biopharmaceuticals Ltd |
|
Jersey |
|
|
|
|
|
AbbVie UK Ltd |
|
Jersey |
|
|
|
|
|
AbbVie Ltd |
|
Korea, South |
|
|
|
|
|
AbbVie SIA |
|
Latvia |
|
|
|
|
|
AbbVie UAB |
|
Lithuania |
|
|
|
|
|
AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S. |
|
Luxembourg |
|
|
|
|
|
AbbVie International S.à r.l. |
|
Luxembourg |
|
|
|
|
|
AbbVie Investments S.à r.l. |
|
Luxembourg |
|
|
|
|
|
AbbVie Overseas S.à r.l. |
|
Luxembourg |
|
|
|
|
|
AbbVie S.à r.l. |
|
Luxembourg |
|
|
|
|
|
AbbVie Sdn. Bhd. |
|
Malaysia |
|
|
|
|
|
AbbVie Farmacéuticos, S.A. de C.V. |
|
Mexico |
|
|
|
|
|
AbbVie B.V. |
|
Netherlands |
|
|
|
|
|
AbbVie Finance B.V. |
|
Netherlands |
|
AbbVie Ireland NL B.V. |
|
Netherlands |
|
|
|
|
|
AbbVie Japan Holdings B.V. |
|
Netherlands |
|
|
|
|
|
AbbVie Logistics B.V |
|
Netherlands |
|
|
|
|
|
AbbVie Nederland Holdings B.V. |
|
Netherlands |
|
|
|
|
|
AbbVie Pharmaceuticals B.V. |
|
Netherlands |
|
|
|
|
|
AbbVie Research B.V. |
|
Netherlands |
|
|
|
|
|
AbbVie Venezuela Holdings B.V. |
|
Netherlands |
|
|
|
|
|
AbbVie Limited |
|
New Zealand |
|
|
|
|
|
AbbVie AS |
|
Norway |
|
|
|
|
|
AbbVie, S. de R.L. |
|
Panama |
|
|
|
|
|
AbbVie Polska Sp. z o.o. |
|
Poland |
|
|
|
|
|
AbbVie Sp. z o.o. |
|
Poland |
|
|
|
|
|
AbbVie, L.da |
|
Portugal |
|
|
|
|
|
AbbVie Promoção, L.da |
|
Portugal |
|
|
|
|
|
AbbVie Corp |
|
Puerto Rico |
|
|
|
|
|
Knoll LLC |
|
Puerto Rico |
|
|
|
|
|
S.C. AbbVie S.R.L. |
|
Romania |
|
|
|
|
|
AbbVie Limited Liability Company |
|
Russia |
|
|
|
|
|
AbbVie Operations Singapore Pte. Ltd. |
|
Singapore |
|
|
|
|
|
AbbVie Pte. Ltd. |
|
Singapore |
|
|
|
|
|
AbbVie Holdings s.r.o. |
|
Slovakia |
|
|
|
|
|
AbbVie s.r.o. |
|
Slovakia |
|
|
|
|
|
AbbVie d.o.o. |
|
Slovenia |
|
|
|
|
|
AbbVie (Pty) Ltd. |
|
South Africa |
|
AbbVie Spain, S.L. |
|
Spain |
|
|
|
|
|
Fundación AbbVie |
|
Spain |
|
|
|
|
|
AbbVie AB |
|
Sweden |
|
|
|
|
|
AbbVie AG |
|
Switzerland |
|
|
|
|
|
AbbVie Biopharmaceuticals GmbH |
|
Switzerland |
|
|
|
|
|
Pharmacyclics Switzerland GmbH |
|
Switzerland |
|
|
|
|
|
AbbVie Ltd. |
|
Thailand 99.9997% |
|
|
|
|
|
AbbVie Sarl |
|
Tunisia |
|
|
|
|
|
AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi |
|
Turkey |
|
|
|
|
|
AbbVie Ltd |
|
United Kingdom |
|
|
|
|
|
AbbVie Australasia Holdings Limited |
|
United Kingdom |
|
|
|
|
|
AbbVie Investments Limited |
|
United Kingdom |
|
|
|
|
|
AbbVie Trustee Company Limited |
|
United Kingdom |
|
|
|
|
|
AbbVie UK Holdco Limited |
|
United Kingdom |
|
|
|
|
|
AbbVie S.A. |
|
Uruguay |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/19/21 AbbVie Inc. 10-K 12/31/20 117:22M |